The therapeutic effectiveness of lysozyme (large scale manufactured hen egg-white lysozyme) is actually based on its ability to control the growth of susceptible bacteria and to modulate host immunity against infections and depressions of immune responses. If the former is based on the first evidence of the biological activity of this enzyme, the second is a relatively recent acquisition of extreme importance for the possibilities offered in terms of the regulation of the functioning of the host's immune system. Antibotic activity and immune stimulating effects are also used together, as in the case of the treatment of gastrointestinal infections, including those originated by therapeutical treatments. Based on these biological properties, in addition to the wide range of therapeutic activities for which lysozyme was exploited in the past, at present the most promising data concern the prevention of bacterial cariogenesis and treatment of cancer patients to improve the effectiveness of anticancer drugs or to allow the host to recover from the immune suppression caused by anticancer treatments. However, lysozyme does not yet hold a clear place as an immune modulating agent, in spite of the fact that it has been shown to stimulate immunity with no difference between experimental animals and human beings. The hope is therefore that doctors will understand its potential and that they will take advantage of the existence of this simple and useful molecule.
Sava G, Benetti A, Ceschia V, Pacor S. Sava G, et al. Anticancer Res. 1989 May-Jun;9(3):583-91. Anticancer Res. 1989. PMID: 2669620 Review.
Burman LG, Lundblad G, Camner P, Fänge R, Lundborg M, Söder P. Burman LG, et al. Lakartidningen. 1991 Oct 30;88(44):3665-8. Lakartidningen. 1991. PMID: 1943384 Swedish.
Aminlari L, Hashemi MM, Aminlari M. Aminlari L, et al. J Food Sci. 2014 Jun;79(6):R1077-90. doi: 10.1111/1750-3841.12460. Epub 2014 May 16. J Food Sci. 2014. PMID: 24837015 Review.
Cooke DG, Blackwell LF. Cooke DG, et al. J Immunoassay Immunochem. 2007;28(2):67-90. doi: 10.1080/15321810701209704. J Immunoassay Immunochem. 2007. PMID: 17424827
Düring K, Porsch P, Mahn A, Brinkmann O, Gieffers W. Düring K, et al. FEBS Lett. 1999 Apr 23;449(2-3):93-100. doi: 10.1016/s0014-5793(99)00405-6. FEBS Lett. 1999. PMID: 10338111
Almeida C, Pedro AQ, Tavares APM, Neves MC, Freire MG. Almeida C, et al. Front Bioeng Biotechnol. 2023 Feb 7;11:1037436. doi: 10.3389/fbioe.2023.1037436. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 36824351 Free PMC article. Review.
Cui L, Huang H, Zhang H, Wang X, Qin X, Tu T, Zhang J, Su X, Yu H, Bai Y, Luo H, Yao B, Wang Y. Cui L, et al. Bioengineered. 2022 May;13(5):13860-13871. doi: 10.1080/21655979.2022.2084496. Bioengineered. 2022. PMID: 35726822 Free PMC article.
Zharkova MS, Golubeva OY, Orlov DS, Vladimirova EV, Dmitriev AV, Tossi A, Shamova OV. Zharkova MS, et al. Front Microbiol. 2021 Dec 17;12:750556. doi: 10.3389/fmicb.2021.750556. eCollection 2021. Front Microbiol. 2021. PMID: 34975782 Free PMC article.
Jiang L, Li Y, Wang L, Guo J, Liu W, Meng G, Zhang L, Li M, Cong L, Sun M. Jiang L, et al. Front Pharmacol. 2021 Dec 3;12:767642. doi: 10.3389/fphar.2021.767642. eCollection 2021. Front Pharmacol. 2021. PMID: 34925025 Free PMC article. Review.
Stabili L, Rizzo L, Caprioli R, Leone A, Piraino S. Stabili L, et al. Mar Drugs. 2021 Oct 31;19(11):619. doi: 10.3390/md19110619. Mar Drugs. 2021. PMID: 34822490 Free PMC article.